North America Startup Funding Rounds
Startups raising capital across North America. Compare the businesses, funding stages and investors active in the region.
- Rounds
- 2,306 Jan 1 – Oct 26, 2026
- Disclosed funding
- $251.5B 1913 disclosed amounts
- Median round
- $23.5M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
 EpiBiologicsCompany profile Develops bispecific antibodies for targeted degradation of extracellular proteins. Develops bispecific antibodies for targeted degradation of extracellular proteins. | $107M | Series B | Biotech | United States | Investors | |
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| A Develops specialized AI systems for regulated industries | $70M | Series B | AI | United States | Investors | |
 Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed | |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50M | Series A | Healthtech | United States | Investors | |
| MT Develops therapies to halt fibrosis in multiple organ systems | $76M | Series B | Biotech | United States | Investors | |
| PS Provides AI-native due diligence for life sciences dealmaking | $20M | Series A | Biotech | United States | Investors | |
| RM Rakuten MedicalCompany profile Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment | $100M | Series FSeries C+ | Biotech | United States | Investors | |
| H Provides AI-powered underwriting technology for mortgage lenders | Undisclosed | StrategicUndisclosed | Fintech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1Y Combinator (YC)
Tractian, Blacksmith, Databuddy Analytics
133rounds3led - 2Andreessen Horowitz (a16z)
ASI, Eka Robotics, Town
98rounds19led - 3General Catalyst
Tractian, Different, Baba
70rounds7led - 4Alumni Ventures
Maxinsights, Daytona, Chariot Claims
60rounds0led - 5Khosla Ventures
Arda Industries, Tolan
59rounds6led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.